News | June 28, 2021
Lonza to expand API manufacturing facility in Nansha, China
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.’s Brovana
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
Entered into a manufacturing partnership with Ocugen, Inc. for manufacturing of COVID-19 vaccine COVAXIN for the US and Canadian markets
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
Subscribe To Our Newsletter & Stay Updated
